Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304).
Ronan Andrew Mc Laughlin, Hayley Thomas, Ian D. Davis, Robert Zielinski, Alastair Thomson, Thean Hsiang Tan, Shahneen Sandhu, M. Neil Reaume, David Pook, Francis Parnis, Scott North, Gavin Marx, John McCaffrey, Ray McDermott, Lisa G. Horvath, Mark Frydenberg, Simon Chowdhury, Kim N., Martin R. Stockler, Christopher Sweeney (2024). Prognostic implications of PSA levels at 7 months in metastatic hormone-sensitive prostate cancer treated with enzalutamide: Landmark analysis of ENZAMET (ANZUP 1304).. , 42(16_suppl), DOI: https://doi.org/10.1200/jco.2024.42.16_suppl.5079.
